HeartFlow logo
HeartFlow Enters into Licensing Agreement with Cedars-Sinai for Coronary
Plaque Assessment Technology
AutoPlaque Technology Will Accelerate HeartFlow’s Efforts to Bring
Plaque Assessment to the HeartFlow Analysis
REDWOOD CITY, Calif. - March 1, 2018 - HeartFlow, Inc. today announced that it has entered
into a licensing and technology transfer agreement with Cedars-Sinai in Los Angeles for
AutoPlaque technology, a software tool used to detect and characterize coronary artery plaque
based on coronary computed tomography angiography (CCTA) images. HeartFlow plans to use
the AutoPlaque technology in its efforts to provide plaque assessment in future products,
providing physicians with more information to help diagnose patients with coronary artery
disease (CAD) and determine optimal treatment pathways.
The assessment of vulnerable plaque - lesions in coronary arteries that have the potential to
rupture and cause acute coronary syndrome (ACS) - is an important area of clinical research.
Results of the EMERALD (Exploring the MEchanism of the plaque Rupture in Acute coronary
syndrome using coronary CT angiography and computationaL fluid Dynamics) study, which
were presented at EuroPCR 2016, demonstrated that the HeartFlow® FFRct Analysis, together
with an assessment of coronary plaque, may help predict which coronary plaques are most
likely to rupture. The HeartFlow FFRct Analysis is a first-of-its-kind non-invasive technology that
provides a personalized 3D model of the heart to help clinicians diagnose and treat patients with
suspected coronary artery disease (CAD).
“In addition to assessing lesion-specific physiology, understanding and characterizing coronary
artery plaque is important in determining the most appropriate treatment path for patients with
suspected CAD. The power of utilizing the AutoPlaque tool in the HeartFlow Analysis may
accelerate our ability to analyze and characterize plaque in coronary arteries,” said John H.
Stevens, M.D., president and chief executive officer, HeartFlow. “HeartFlow is committed to
looking beyond our initial FFRct offering to additional novel products that can help clinicians
address other important clinical factors in the diagnosis and treatment of CAD and develop
solutions that we believe will benefit patients who may be most at risk for ACS.”
CAD, which today affects 16.8 million Americans,i develops when the coronary arteries narrow,
reducing blood flow to the heart and causing angina (chest pain), myocardial infarction (heart
attack) and death. Acute Coronary Syndrome (ACS) is a life-threatening condition that occurs
due to decreased blood flow to the heart, often because of a sudden rupture of plaque inside a
coronary artery. ACS encompasses both unstable angina and myocardial infarction. In the
United States, an ACS occurs every 25 seconds and someone dies from an ACS-related event
every minute.ii Each year, approximately 1.4 million Americans are hospitalized with ACS, of
whom 810,000 are hospitalized for myocardial infarction.iii Studies have shown that plaque
rupture causes approximately 75 percent of fatal myocardial infarctions.iv
33433896 v1
About the HeartFlow FFRct Analysis
Clinicians diagnosing someone with suspected CAD want to know as definitively as possible if
the individual has a significant blockage in their coronary arteries. They also want to know the
impact of that blockage on blood flow so they can best determine which treatment pathway is
appropriate (e.g., medical management, stenting or coronary artery bypass grafting).
Data from a patient’s non-invasive CCTA are securely uploaded from the hospital’s system to
the cloud. HeartFlow leverages deep learning to create a personalized, digital 3D model of the
patient’s coronary arteries. The HeartFlow Analysis then uses powerful computer algorithms to
solve millions of complex equations to simulate blood flow and assess the impact of blockages
on coronary blood flow. The HeartFlow FFRct Analysis is provided via a secure online interface
to offer actionable information to enable clinicians to determine the optimal course of treatment.
To date, clinicians around the world have used the HeartFlow Analysis for more than 15,000
patients to aid in the diagnosis of heart disease.
This technology has been demonstrated to reduce unnecessary and invasive diagnostic
coronary angiography procedures, which can be associated with bleeding, stroke, major blood
vessel damage and other serious complications. It also significantly reduces healthcare costs
for hospitals.v
About HeartFlow, Inc.
HeartFlow, Inc. is a medical technology company redefining the way heart disease is diagnosed
and treated. Our non-invasive HeartFlow FFRct Analysis leverages deep learning to create a
personalized 3D model of the heart. By using this model, clinicians can better evaluate the
impact a blockage has on blood flow and determine the best treatment for patients. Our
technology is reflective of our Silicon Valley roots and incorporates decades of scientific
evidence with the latest advances in artificial intelligence. The HeartFlow FFRct Analysis is
commercially available in the United States, Canada, Europe and Japan. For more information,
# # #
Media Contact:
Jennie Kim
ii Wachira JK, Stys TP. Cardiovascular disease and bridging the diagnostic gap. S D Med. 2013;66:366-369.
iii Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc.
iv Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc.
v Douglas PS, DeBruyne B, Pontone G., Patel MR, et al. One-year outcomes of FFRCT-guided care in patients with
suspected coronary disease: The PLATFORM Study. J Am Coll Cardiol. 2016;68(5),435-45.
33433896 v1